Opus Genetics (IRD) Amortizatization of Intangibles (2018 - 2020)
Opus Genetics (IRD) posted quarterly Amortizatization of Intangibles of -$1000.0 for Q4 2020, down 100.11% year-over-year from $927230.0 in Q1 2020, and down 112.5% quarter-over-quarter from $8000.0 in Q3 2020.
Powered by 
Analysis
Opus Genetics (IRD) Amortizatization of Intangibles (2018 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Amortizatization of Intangibles for 3 consecutive years, with -$1000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Amortizatization of Intangibles fell 100.11% year-over-year to -$1000.0; the TTM figure through Sep 2021 stood at -$1000.0 (down 100.06% YoY), while the FY2020 annual figure was $873000.0, down 13.91% from the prior year.
- Amortizatization of Intangibles slipped to -$1000.0 in Q4 2020 per IRD's latest filing, from $8000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $927230.0 in Q4 2019 and bottomed at -$14907.0 in Q1 2018.
- Historically, Amortizatization of Intangibles has averaged $154812.4 across 3 years, with a median of $13249.5 in 2019.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles surged 22491.45% — and 2020, when it slumped 100.11%.
- Opus Genetics' Amortizatization of Intangibles stood at -$4141.0 in 2018, then jumped by 22491.45% to $927230.0 in 2019, then plunged by 100.11% to -$1000.0 in 2020.
- Business Quant data shows IRD's Amortizatization of Intangibles at -$1000.0 in Q4 2020, $8000.0 in Q3 2020, and $500000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Dec 31, 2019 | 927,230.00 |
| Sep 30, 2019 | 30,751.00 |
| Jun 30, 2019 | 37,520.00 |
| Mar 31, 2019 | 18,499.00 |
| Dec 31, 2018 | -4,141.00 |
| Sep 30, 2018 | -8,606.00 |
| Jun 30, 2018 | -11,597.00 |
| Mar 31, 2018 | -14,907.00 |